Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
Ya-Jung WangYa-Ning ChanYou-Wun JhengChih-Jung WuMing-Wei LinLing-Ming TsengYi-Fang TsaiLiang-Chih LiuPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)
The change of CIPN prevalence and severity were significant over time in survivors newly diagnosed with breast cancer. Specifically, the severest and highest CIPN was detected at chemotherapy completion. Survivors remained suffering from CIPN 3 months after chemotherapy completion. Besides, mild to moderate correlations between clinician-assessed and patient-reported CIPN were identified.